November 21, 2008 - Basilea Pharmaceutica Ltd. announces that Zevtera (ceftobiprole medocaril), the first-in-class anti-MRSA broad-spectrum cephalosporin, received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of complicated skin and soft tissue infections.
The details can be read here.
No comments:
Post a Comment